Alendronate Sodium — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	0.5-1 mg/kg	q24h	Duration: Variable; often 2-4 weeks, then reassess Notes: Administer on an empty stomach, at least 30-60 minutes before food. Give with plain water. Do not give with food, milk, or other medications. Monitor serum calcium and renal function.
Cat	PO	0.5-1 mg/kg	q24h	Duration: Variable; often 2-4 weeks, then reassess Notes: Administer on an empty stomach. Cats may be difficult to pill; ensure adequate water intake. Monitor renal function and serum calcium.
Horse	PO	0.1-0.2 mg/kg	q24h	Duration: Variable; limited data Notes: Not commonly used; use with caution. Administer on an empty stomach.
Rabbit	PO	0.5-1 mg/kg	q24h	Duration: Variable; monitor calcium levels Notes: Off-label use. Administer on an empty stomach. Ensure adequate hydration.
Reptiles	PO	2-5 mg/kg	q24h	Duration: Variable; monitor calcium levels Notes: Off-label use. Administer on an empty stomach. Ensure adequate hydration.

Clinical Indications & Species Uses

General Indications

Management of hypercalcemia (especially malignancy-associated)
Reduction of bone resorption in osteolytic conditions

Dog (Canine)

Hypercalcemia associated with malignancy (e.g., lymphoma, anal sac adenocarcinoma)
Idiopathic hypercalcemia
Osteoporosis (rarely used)
Calcinosis cutis (off-label)
Bone resorption disorders

Cat (Feline)

Hypercalcemia (idiopathic or malignancy-associated)
Feline odontoclastic resorptive lesions (FORL) (off-label)
Osteoporosis (rarely used)

Rabbit & Small Mammals

Hypercalcemia (off-label)
Dental disease with bone resorption (off-label)

Exotic & Other Species

Hypercalcemia in reptiles (off-label)
Metabolic bone disease in reptiles (off-label)

Pharmacology & Mechanism of Action

Drug Class: Bisphosphonate | Pharmacological Group: Bone resorption inhibitor

Mechanism of Action: Alendronate sodium is a bisphosphonate that inhibits osteoclast-mediated bone resorption. It binds to hydroxyapatite crystals in bone, and when osteoclasts resorb bone containing the drug, it is released and taken up by the osteoclasts, leading to disruption of the mevalonate pathway and inhibition of farnesyl pyrophosphate synthase. This results in osteoclast apoptosis and reduced bone turnover, thereby increasing bone mineral density and decreasing fracture risk.

Pharmacodynamics: Alendronate reduces bone turnover markers (e.g., N-telopeptide, deoxypyridinoline) within weeks of administration. It increases bone mineral density in both axial and appendicular skeleton. In veterinary patients, it is used to manage hypercalcemia and pathological bone resorption. Its effects are long-lasting due to its high affinity for bone mineral, and it may remain in bone for years after discontinuation.

⚡ Pharmacokinetics Summary

Absorption: Oral absorption is poor, with bioavailability approximately 0.6-0.7% in humans when taken on an empty stomach with plain water. Food, especially calcium-containing foods, significantly reduces absorption. In dogs, similar low bioavailability is expected. It must be administered on an empty stomach, at least 30-60 minutes before the first meal of the day.

Distribution: After absorption, alendronate is rapidly distributed to bone, where it binds to hydroxyapatite. It has a large volume of distribution in bone tissue. Soft tissue distribution is minimal. It does not cross the blood-brain barrier significantly.

Metabolism: Alendronate is not metabolized in the body. It is excreted unchanged, primarily by the kidneys.

Excretion: Renal excretion is the primary route of elimination. Approximately 50% of the absorbed dose is excreted in urine within 72 hours. The remainder is retained in bone for long periods, with a terminal half-life in bone estimated to be years.

Half-Life: In plasma, the half-life is short (approximately 1-2 hours in humans), but the terminal half-life in bone is estimated to be 10 years or more in humans. In dogs, similar pharmacokinetics are expected.

Bioavailability: Oral bioavailability is very low, approximately 0.6-0.7% in humans. In dogs, it is similarly low, and it is recommended to administer on an empty stomach to maximize absorption.

Protein Binding: Approximately 78% bound to plasma proteins in humans.

Available Formulations & Strengths

Oral Tablet 5 mg, 10 mg, 35 mg, 70 mg (PO)

Oral Solution 70 mg/75 mL (PO)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to alendronate or other bisphosphonates
Severe renal impairment (creatinine clearance < 35 mL/min in humans; use with caution in animals with renal disease)
Hypocalcemia
Esophageal disorders that delay esophageal emptying (e.g., stricture, achalasia)
Inability to stand or maintain an upright posture for at least 30 minutes after oral administration (in humans; in animals, ensure they remain upright to prevent esophageal irritation)
Pregnancy and lactation (safety not established; use only if clearly needed)

Warnings & Clinical Precautions:

Administer on an empty stomach with plain water, at least 30-60 minutes before the first food of the day.
Do not administer with food, milk, or other medications, as absorption is significantly reduced.
Ensure adequate hydration during therapy.
Monitor renal function, serum calcium, phosphorus, and electrolytes periodically.
Use with caution in animals with gastrointestinal disease (e.g., esophagitis, gastritis).
May cause gastrointestinal irritation; if signs of esophagitis or gastric ulceration occur, discontinue and seek veterinary care.
In animals with pre-existing renal disease, dose adjustment may be necessary; use with caution.
Not recommended for use in young, growing animals due to potential effects on bone development.
Do not use in pregnant or lactating animals unless the benefits outweigh the risks.

Adverse Effects & Reactions

Common:

Gastrointestinal upset (vomiting, diarrhea, anorexia)
Esophageal irritation or ulceration (if not administered properly)
Hypocalcemia
Hypophosphatemia

Serious / Severe:

Esophageal stricture or perforation (rare but serious)
Renal toxicity (especially with rapid IV administration; not applicable for oral)
Osteonecrosis of the jaw (rare, reported in humans; not reported in animals)
Severe musculoskeletal pain

Rare:

Atrial fibrillation (in humans; not reported in animals)
Hypersensitivity reactions (urticaria, angioedema)
Ocular inflammation (uveitis, scleritis)

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Calcium supplements, antacids, oral iron, magnesium-containing products	Reduce absorption of alendronate; administer at least 2 hours apart.	Moderate
NSAIDs (e.g., aspirin, carprofen)	Increased risk of gastrointestinal irritation and ulceration.	Moderate
Aminoglycosides	Potential additive hypocalcemic effect.	Mild
Corticosteroids	May increase risk of gastrointestinal ulceration.	Moderate
Loop diuretics (e.g., furosemide)	May increase risk of hypocalcemia.	Mild

Overdose & Toxicity Management

Signs of Toxicity:

Hypocalcemia
Hypophosphatemia
Gastrointestinal signs (vomiting, diarrhea, abdominal pain)
Esophageal irritation or ulceration
Renal impairment

Emergency Treatment Protocol: There is no specific antidote. Treatment is symptomatic and supportive. Administer milk or antacids to bind the drug and reduce absorption. Monitor serum calcium, phosphorus, and renal function. Provide intravenous fluids to maintain hydration and promote renal excretion. In severe hypocalcemia, administer calcium gluconate IV as needed. Gastrointestinal protectants (e.g., sucralfate) may be used. Esophageal injury should be managed with supportive care and possibly endoscopic evaluation.

Food Animal Withdrawal Times

Not approved for use in food animals. Withdrawal times are not established. Use in food animals is prohibited or requires a very long withdrawal period; consult regulatory authorities.

Storage, Handling & Regulatory Information

Storage Temperature: Store at room temperature (20-25°C, 68-77°F). Protect from moisture and light.

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Keep in original container, tightly closed. Do not remove desiccant. Store away from heat and direct sunlight.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use. Approved for human use (e.g., Fosamax). In veterinary medicine, it is used extra-label.

Extra-Label (Off-Label) Use: In the US, extra-label use of alendronate in animals is permitted under AMDUCA (Animal Medicinal Drug Use Clarification Act) for non-food animals. For food animals, extra-label use is prohibited if the drug is not approved for that species and if there are no established withdrawal times. Use in food animals is generally not recommended.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Alendronate sodium is a potent bisphosphonate used in veterinary medicine primarily for the management of hypercalcemia, especially malignancy-associated hypercalcemia, and for conditions involving excessive bone resorption. It is important to administer it correctly: on an empty stomach, with plain water, and to keep the animal upright for at least 30 minutes after administration to prevent esophageal irritation. The drug has a very low oral bioavailability, so strict adherence to administration instructions is critical. Clinical response should be monitored by measuring serum calcium levels, bone resorption markers, and renal function. Because of its long half-life in bone, effects may persist after discontinuation. Use in young animals should be avoided due to potential effects on bone development. In cats, careful administration is needed to avoid stress and ensure the entire dose is swallowed. For exotic species, dosing is often extrapolated from other species and should be based on careful monitoring. Always consider the underlying cause of hypercalcemia and treat accordingly. Alendronate is not a substitute for definitive treatment of the underlying disease (e.g., tumor removal).

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)